GENFIT's GNS561 Combination Therapy Shows Tumor Control Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy ?
Source: Globenewswire
- Clinical Trial Progress: The ongoing Phase 1b study shows that the combination of GNS561 and MEK inhibitors achieves disease stabilization in all evaluable patients, with tumor shrinkage observed in a subset, indicating potential efficacy in difficult-to-treat cholangiocarcinoma.
- Patient Recruitment Status: No dose-limiting toxicities have been reported to date, enabling the recruitment of a third patient cohort, with recommended Phase 2 doses expected in 1H26, reflecting a positive outlook for the study.
- Addressing Treatment Needs: The combination therapy has achieved disease control in patients who have failed multiple prior treatments, fulfilling a critical unmet medical need and potentially offering new hope for these patients.
- Future Development Plans: The Phase 1b dose escalation will continue as planned, with new data expected in Q1 2026 to support the initiation of Phase 2, further validating the clinical benefits of this combination approach.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
